BioStock: Chordate continues its marketing activities and exit strategy

In 2023, Chordate Medical has taken steps forward in the commercial progress with the migraine treatment Ozilia. The long-term goal is to sell the company. To continue working towards this goal, the company intends to carry out a rights issue of 41.8 MSEK. BioStock reached out to CEO Anders Weilandt to find out more. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/chordate-continues-its-marketing-activities-and-exit-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se